The Prognostic Value of Pre-Treatment Leukocytosis in Patients with Previously Treated, Stage IIIB/IV Non-Small Cell Lung Cancer Treated with the IGF-1R Pathway Modulator AXL1717 or Docetaxel; a Retrospective Analysis of a Phase II Trial

Georg Holgersson,Michael Bergqvist,Jonas Nilsson,Marcus Thuresson,Johan Harmenberg,Stefan Bergström

The Prognostic Value of Pre-Treatment Leukocytosis in Patients with Previously Treated, Stage IIIB/IV Non-Small Cell Lung Cancer Treated with the IGF-1R Pathway Modulator AXL1717 or Docetaxel; a Retrospective Analysis of a Phase II Trial

2017

Georg Holgersson
Michael Bergqvist
Jonas Nilsson
Marcus Thuresson
Johan Harmenberg
Stefan Bergström

The Prognostic Value of Pre-Treatment Leukocytosis in Patients with Previously Treated, Stage IIIB/IV Non-Small Cell Lung Cancer Treated with the IGF-1R Pathway Modulator AXL1717 or Docetaxel; a Retrospective Analysis of a Phase II Trial

Keywords:

Gynecology
Leukocytosis
Immunology
Anemia
Cancer research
Medicine
Lung cancer
Thrombocytosis
Docetaxel
Internal medicine
Surgery
Performance status
Hemoglobin
Gastroenterology
Phases of clinical research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations